FindMyKOL
Clinical trialNCT01445119CompletedPhase 1Interventional

A Phase I Trial of Enzastaurin (LY317615) in Combination With Carboplatin in Adults With Recurrent Gliomas

NCT01445119 is a phase 1 interventional trial sponsored by Eli Lilly and Company. As of 21 Nov 2026, it is completed. It studies Carboplatin and Enzastaurin in Recurrent Gliomas. The registry lists an enrollment of 58 participants at 1 site in 1 country. The registry lists a start date of 31 Jan 2007 and a primary completion date of 31 Jul 2013.

SponsorEli Lilly and Company →Enrollment58Recurrent Gliomas
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT01445119
FieldValue
Registry IDNCT01445119
StatusCompleted
PhasePhase 1
Study typeInterventional trial
Lead sponsorEli Lilly and Company
Enrollment58
Registered sites1
Countries1
ConditionsRecurrent Gliomas
DrugsCarboplatin and Enzastaurin
Start31 Jan 2007
Primary completion31 Jul 2013
Study completion31 Jul 2013
Last update posted28 Aug 2013

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study will evaluate the safety and effectiveness of Enzastaurin, an experimental drug that may prevent the growth of tumor vessels, in combination with Carboplatin, for patients who have a glioma, a type of brain tumor. Carboplatin is used for treating many kinds of cancers, though not recurrent gliomas. Tumor growth involves new cancer cell formation and accumulation, requiring a blood supply. Research shows that brain tumor cells can produce substances that stimulate new blood vessel formation. This study will look into whether the combination of drugs can stop that process. Patients ages 18 and older who have recurring gliomas, who are not pregnant or breast feeding, and who do not have serious diseases may be eligible for this study. About 96 patients will participate for 1 year. They will have a physical examination, give blood and urine samples for analysis, and undergo magnetic resonance imaging (MRI) or computed tomography (CT) scans regarding tumor growth, and perhaps an electrocardiogram. Patients may also undergo a dynamic MRI with spectroscopy or PET scan (positron emission tomography), to distinguish a live tumor from a dying one. Researchers are studying patients taking a certain type of antiseizure medicine and patients who are not taking it because some antiseizure medicines may change the way the body handles a drug such as Enzastaurin. There will be two groups of participants, with 16 to 48 each. Group A is not taking enzyme-inducing antiseizure drugs, and Group B is taking such drugs. In Groups A and B are four dose levels, with 4 to12 patients at each level. Patients' doctors will tell them which group they belong to and how much Enzastaurin and Carboplatin they will take. Treatment consists of Enzastaurin every day for 5 weeks in Cycle 1 only and for 4 weeks beginning with Cycle 2 (each 4-week period as a cycle). Patients take Enzastaurin within 30 minutes after a meal. History, physical, and neurological examinations are repeated at the end of Cycle 1 and then every 4 weeks. Patients will have a repeat head MRI or CT scan before each cycle. If they tolerate the drugs without serious side effects and the tumor is not growing, they may continue with another cycle of Enzastaurin, taking the tablets every day, and Carboplatin being infused on Day 8 of Cycle 1 and on Day 1 of each additional cycle. Routine lab tests are done regularly. Patients will continue the 4-week cycles of treatment for as long as they have no serious side effects and there are no signs of tumor growth. Side effects of Enzastaurin may be fatigue, constipation, cough, and nausea. In men, there may be a decrease in sperm count. Carboplatin can lead to low counts in blood cells and platelets, and there may also be an allergic reaction. Vomiting is a likely side effect. At injection sites, there may be redness, swelling, and pain. This study may or may not have a direct benefit for participants. However, information gained may help the sponsor of the study, Eli Lilly and Company, and may help patients in the future who have gliomas.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Maryland, United States1 site
  • National Institutes of Health Clinical Center, 9000 Rockville Pike

    Bethesda

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinoisILIndianaINOhioOHPennsylvaniaPANew JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMaryland: 1 siteMD1DelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth CarolinaNCSouth CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgiaGAHawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Carboplatin →Enzastaurin
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT01445119

Each answer restates registry values shown on this page.

What is NCT01445119?

NCT01445119 is a phase 1 interventional trial sponsored by Eli Lilly and Company. It studies Carboplatin and Enzastaurin in Recurrent Gliomas.

Who leads NCT01445119?

The registry names Joohee Sul, M.D. (principal investigator, National Cancer Institute (NCI)) as the overall official.

Where does NCT01445119 run?

The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT01445119 study?

The registered drug and biological interventions are Carboplatin and Enzastaurin.

When did NCT01445119 end?

The registry lists a primary completion date of 31 Jul 2013 and a study completion date of 31 Jul 2013. The sponsor last updated the record on 28 Aug 2013.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.